PhilSPEN Online Journal of Parenteral and Enteral Nutrition

Back to Total Names Codes

(Article 106 | POJ_0100)

Submitted Abstracts

PENSA 2017 Congress

Submitted: August 12, 2017

Abstract ID = 70 | Classification: (5) - Enteral nutrition

Title: Effect of omega-3 containing enteral formula feeding to the TLC of cancer patients in comparison to non- omega-3 containing enteral formula feeding

Author(s): Manansala, L.A.J. and Hernando, A.Y.J.

Institution where study was conducted: Clinical Nutrition Management Services (CNMS), Manila Doctors Hospital, Manila, Philippines

Keywords: omega-3-fatty acids, TLC, cancer, enteral

Background: The TLC (Total Lymphocyte Count) has been used to determine the risk of nutrition related problem and as an indicator for cancer survival and recovery. Lymphopenia is a common cancer malady. Omega-3 is known for its effects in increasing the body’s anti-inflammatory cells thus many cancer specific enteral nutrition formula contains this oil.

Objectives: The objective of the study is to determine the effect of Omega- 3 Containing Enteral Formula (O-3EF) intake to the TLC of cancer patients and compare it to the TLC of cancer patients being fed with non-O-3EF.

Methods: All CNMS cancer patients fed via enteral tube with O-3EF and Non-O-3EF for at least 2 days and was admitted at Manila Doctors Hospital from February 2016 to May 2017 was separated into two groups. Pre and Post TLC of each patient was gathered and compared between the groups using the T-test and their mean TLC increase.

Results: A mean increase of 479.5 in TLC results was observed for the group fed with O- 3EF compared to a mean increase of 28.5 in TLC for the group fed with non O-3EF. The t-test of the Post TLC results between the groups is .73 for the P(T<=t) two-tail, and .37 for the P(T<=t) one-tail making the difference significant.

Conclusion: It could be concluded that the use of Omega-3 rich enteral formula has a positive effect in the increase of the TLC of cancer patients regardless of their cancer type, age and disease prognosis in comparison to patients who used non O-3EF.